Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-13 08:55 am Sale | 2024-12-31 | 13G | Nuvalent, Inc. NUVL | James E. Flynn | 23,582,278 27.590% | -1,997,612 (-7.81%) | Filing History |
| 2025-01-31 09:54 am Purchase | 2024-12-31 | 13G | Nuvalent, Inc. NUVL | VANGUARD GROUP INC | 4,499,864 6.850% | 1,160,014 (+34.73%) | Filing History |
| 2024-11-14 4:50 pm Purchase | 2024-09-30 | 13G | Nuvalent, Inc. NUVL | PERCEPTIVE ADVISORS LLC | 2,979,235 4.600% | 61,244 (+2.10%) | Filing History |
| 2024-11-14 4:34 pm Purchase | 2024-09-30 | 13G | Nuvalent, Inc. NUVL | Paradigm Biocapital Advisors LP | 5,000,000 7.800% | 1,141,992 (+29.60%) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Nuvalent, Inc. NUVL | BlackRock Inc. BLK | 3,624,981 5.600% | 0 (Unchanged) | Filing History |
| 2024-10-24 2:02 pm Purchase | 2024-09-30 | 13G | Nuvalent, Inc. NUVL | BlackRock Inc. BLK | 3,624,981 5.600% | 3,624,981 (New Position) | Filing History |
| 2024-05-15 6:39 pm Purchase | 2024-05-15 | 13G | Nuvalent, Inc. NUVL | James E. Flynn | 25,579,890 33.990% | 102,114 (+0.40%) | Filing History |
| 2024-03-29 5:16 pm Unchanged | 2024-03-27 | 13D | Nuvalent, Inc. NUVL | Bain Capital Life Sciences Fund II L.P. | 2,400,630 4.100% | 0 (Unchanged) | Filing History |
| 2024-02-14 4:08 pm Purchase | 2023-12-31 | 13G | Nuvalent, Inc. NUVL | Paradigm Biocapital Advisors LP | 3,858,008 6.700% | 478,928 (+14.17%) | Filing History |
| 2024-02-14 3:49 pm Sale | 2023-12-31 | 13G | Nuvalent, Inc. NUVL | Fairmount Funds Management LLC | 1,924,626 3.400% | -864,355 (-30.99%) | Filing History |
| 2024-02-13 5:09 pm Purchase | 2023-12-29 | 13G | Nuvalent, Inc. NUVL | VANGUARD GROUP INC | 3,339,850 5.720% | 3,339,850 (New Position) | Filing History |
| 2024-02-12 5:34 pm Purchase | 2023-12-31 | 13G | Nuvalent, Inc. NUVL | James E. Flynn | 25,477,776 35.010% | 6,110 (+0.02%) | Filing History |
| 2024-02-09 09:28 am Purchase | 2024-02-08 | 13G | Nuvalent, Inc. NUVL | FMR LLC | 8,725,070 14.942% | 1,105,510 (+14.51%) | Filing History |
| 2024-01-02 4:11 pm Purchase | 2023-12-20 | 13G | Nuvalent, Inc. NUVL | PERCEPTIVE ADVISORS LLC | 2,917,991 5.100% | 2,917,991 (New Position) | Filing History |
| 2023-10-30 5:12 pm Purchase | 2023-10-19 | 13G | Nuvalent, Inc. NUVL | Paradigm Biocapital Advisors LP | 3,379,080 5.900% | 3,379,080 (New Position) | Filing History |
| 2023-10-20 4:30 pm Unchanged | 2023-10-19 | 13D | Nuvalent, Inc. NUVL | Bain Capital Life Sciences Fund II L.P. | 2,400,630 4.200% | 0 (Unchanged) | Filing History |
| 2023-02-14 3:45 pm Purchase | 2022-12-31 | 13G | Nuvalent, Inc. NUVL | Fairmount Funds Management LLC | 2,788,981 5.470% | 183,857 (+7.06%) | Filing History |
| 2023-02-10 2:32 pm Purchase | 2022-12-31 | 13G | Nuvalent, Inc. NUVL | James E. Flynn | 25,471,666 39.250% | 4,777 (+0.02%) | Filing History |
| 2023-02-09 12:01 pm Purchase | 2023-02-09 | 13G | Nuvalent, Inc. NUVL | FMR LLC | 7,619,560 14.999% | 1,192,253 (+18.55%) | Filing History |
| 2022-11-14 4:42 pm Purchase | 2022-11-03 | 13G | Nuvalent, Inc. NUVL | James E. Flynn | 25,466,889 39.240% | 690,611 (+2.79%) | Filing History |